{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:19Z","timestamp":1792172539535,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Grant for Implementation of Advanced Medicine","award":["\u5148\u9032 107"],"award-info":[{"award-number":["\u5148\u9032 107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12282-026-01828-5","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:30:41Z","timestamp":1770265841000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Venlafaxine reduces hot flashes in hormone receptor-positive breast cancer patients receiving tamoxifen: a prospective single-arm, open-label trial"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1656-6629","authenticated-orcid":false,"given":"Riko","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Kamohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohei","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachie","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Iguchi-Manaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7361-3647","authenticated-orcid":false,"given":"Hiroko","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"1828_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-007-9548-1","volume":"107","author":"D Cella","year":"2008","unstructured":"Cella D, Fallowfield LJ. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2008;107:167\u201380. https:\/\/doi.org\/10.1007\/s10549-007-9548-1.","journal-title":"Breast Cancer Res Treat"},{"key":"1828_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, L\u00e1ng I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1412379.","journal-title":"N Engl J Med"},{"key":"1828_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1200\/JCO.2003.07.071","volume":"21","author":"AH Partridge","year":"2003","unstructured":"Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602\u20136. https:\/\/doi.org\/10.1200\/JCO.2003.07.071.","journal-title":"J Clin Oncol"},{"key":"1828_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.25485","volume":"5","author":"X Hu","year":"2022","unstructured":"Hu X, Walker MS, Stepanski E, Kaplan CM, Martin MY, Vidal GA, et al. Racial differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor\u2013positive breast cancer. JAMA Netw Open. 2022;5:e2225485. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25485.","journal-title":"JAMA Netw Open"},{"key":"1828_CR5","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1188\/02.ONF.E16-E25","volume":"29","author":"JS Carpenter","year":"2002","unstructured":"Carpenter JS, Johnson D, Wagner L, Andrykowski M. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum. 2002;29:E16\u201325. https:\/\/doi.org\/10.1188\/02.ONF.E16-E25.","journal-title":"Oncol Nurs Forum"},{"key":"1828_CR6","unstructured":"NCCN. NCCN clinical practice guidelines in oncology."},{"key":"1828_CR7","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1200\/JCO.2010.29.9230","volume":"28","author":"L Bordeleau","year":"2010","unstructured":"Bordeleau L, Pritchard KI, Loprinzi CL, Ennis M, Jugovic O, Warr D, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol. 2010;28:5147\u201352. https:\/\/doi.org\/10.1200\/JCO.2010.29.9230.","journal-title":"J Clin Oncol"},{"key":"1828_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/01.AOG.0000147840.06947.46","volume":"105","author":"ML Evans","year":"2005","unstructured":"Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol. 2005;105:161\u20136. https:\/\/doi.org\/10.1097\/01.AOG.0000147840.06947.46.","journal-title":"Obstet Gynecol"},{"key":"1828_CR9","volume-title":"Medical genetics summaries","author":"L Dean","year":"2012","unstructured":"Dean L. Venlafaxine therapy and CYP2D6 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. National Center for Biotechnology Information: Bethesda (MD); 2012."},{"key":"1828_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1097\/FTD.0000000000000854","volume":"43","author":"H Komahashi-Sasaki","year":"2021","unstructured":"Komahashi-Sasaki H, Yasui-Furukori N, Sasaki T, Shinozaki M, Hayashi Y, Kato K, et al. Effects of CYP2D6 genotypes on venlafaxine metabolism in Japanese psychiatric patients with depression. Ther Drug Monit. 2021;43:681\u20137. https:\/\/doi.org\/10.1097\/FTD.0000000000000854.","journal-title":"Ther Drug Monit"},{"key":"1828_CR11","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4088\/JCP.08r04856blu","volume":"70","author":"JE Desmarais","year":"2009","unstructured":"Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70:1688\u201397. https:\/\/doi.org\/10.4088\/JCP.08r04856blu.","journal-title":"J Clin Psychiatry"},{"key":"1828_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.maturitas.2011.12.003","volume":"71","author":"T Guttuso Jr.","year":"2012","unstructured":"Guttuso T Jr., DiGrazio WJ, Reddy SY. Review of hot flash diaries. Maturitas. 2012;71:213\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2011.12.003.","journal-title":"Maturitas"},{"key":"1828_CR13","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.talanta.2014.10.040","volume":"132","author":"MV Antunes","year":"2015","unstructured":"Antunes MV, Raymundo S, de Oliveira V, Staudt DE, G\u00f6ssling G, Peteffi GP, et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots\u2014development, validation and clinical application during breast cancer adjuvant therapy. Talanta. 2015;132:775\u201384. https:\/\/doi.org\/10.1016\/j.talanta.2014.10.040.","journal-title":"Talanta"},{"key":"1828_CR14","doi-asserted-by":"publisher","first-page":"10186","DOI":"10.1021\/ac102337d","volume":"82","author":"M Jaremko","year":"2010","unstructured":"Jaremko M, Kasai Y, Barginear MF, Raptis G, Desnick RJ, Yu C. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry. Anal Chem. 2010;82:10186\u201393. https:\/\/doi.org\/10.1021\/ac102337d.","journal-title":"Anal Chem"},{"key":"1828_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jchromb.2018.04.033","volume":"1087","author":"G Gu","year":"2018","unstructured":"Gu G, Black M, Cookson C, Fiorella A, Li Y, Gorman SH, et al. Validation of an LC-MS\/MS method for simultaneous quantification of venlafaxine and its five metabolites in rat plasma and its application in a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1087:29\u201335. https:\/\/doi.org\/10.1016\/j.jchromb.2018.04.033.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1828_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.2217\/pgs-2020-0105","volume":"21","author":"K Doki","year":"2020","unstructured":"Doki K, Shirayama Y, Sekiguchi Y, Aonuma K, Kohda Y, Ieda M, et al. Effect of CYP2D6 genetic polymorphism on peak propafenone concentration: no significant effect of CYP2D6*10. Pharmacogenomics. 2020;21:1279\u201388. https:\/\/doi.org\/10.2217\/pgs-2020-0105.","journal-title":"Pharmacogenomics"},{"key":"1828_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1001\/jamainternmed.2014.1891","volume":"174","author":"H Joffe","year":"2014","unstructured":"Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174:1058\u201366. https:\/\/doi.org\/10.1001\/jamainternmed.2014.1891.","journal-title":"JAMA Intern Med"},{"key":"1828_CR18","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(00)03403-6.","journal-title":"Lancet"},{"key":"1828_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89:718\u201325. https:\/\/doi.org\/10.1038\/clpt.2011.32.","journal-title":"Clin Pharmacol Ther"},{"key":"1828_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30\u20139. https:\/\/doi.org\/10.1093\/jnci\/dji005.","journal-title":"J Natl Cancer Inst"},{"key":"1828_CR21","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/j.clbc.2021.10.003","volume":"22","author":"M Bradbury","year":"2022","unstructured":"Bradbury M, Hutton B, Beltran-Bless A-A, Alzahrani M, Lariviere T, Fernandes R, et al. Time to update evidence-based guideline recommendations about concurrent tamoxifen and antidepressant use? A systematic review. Clin Breast Cancer. 2022;22:e362\u201373. https:\/\/doi.org\/10.1016\/j.clbc.2021.10.003.","journal-title":"Clin Breast Cancer"},{"key":"1828_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/bcp.13788","volume":"85","author":"T Haslemo","year":"2019","unstructured":"Haslemo T, Eliasson E, Juki\u0107 MM, Ingelman-Sundberg M, Molden E. Significantly lower CYP2D6 metabolism measured as the O\/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients. Br J Clin Pharmacol. 2019;85:194\u2013201. https:\/\/doi.org\/10.1111\/bcp.13788.","journal-title":"Br J Clin Pharmacol"},{"key":"1828_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s002280050737","volume":"56","author":"T Fukuda","year":"2000","unstructured":"Fukuda T, Nishida Y, Zhou Q, Yamamoto I, Kondo S, Azuma J. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol. 2000;56:175\u201380. https:\/\/doi.org\/10.1007\/s002280050737.","journal-title":"Eur J Clin Pharmacol"},{"key":"1828_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes14051095","volume":"14","author":"M Radosavljevic","year":"2023","unstructured":"Radosavljevic M, Svob Strac D, Jancic J, Samardzic J. The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes (Basel). 2023;14:1095. https:\/\/doi.org\/10.3390\/genes14051095.","journal-title":"Genes (Basel)"},{"key":"1828_CR25","doi-asserted-by":"publisher","DOI":"10.1017\/S2045796024000520","volume":"33","author":"CB Kamp","year":"2024","unstructured":"Kamp CB, Petersen JJ, Faltermeier P, Juul S, Siddiqui F, Moncrieff J, et al. The risks of adverse events with venlafaxine for adults with major depressive disorder: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Epidemiol Psychiatr Sci. 2024;33:e51. https:\/\/doi.org\/10.1017\/S2045796024000520.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"1828_CR26","unstructured":"Singh D, Saadabadi A. Venlafaxine. [Updated 2024 Feb 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535363\/"},{"key":"1828_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ctrv.2016.11.012","volume":"52","author":"RA Leon-Ferre","year":"2017","unstructured":"Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev. 2017;52:82\u201390. https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.012.","journal-title":"Cancer Treat Rev"},{"key":"1828_CR28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091\u2013102. https:\/\/doi.org\/10.1016\/S0140-6736(23)00085-5.","journal-title":"Lancet"},{"key":"1828_CR29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1749-6632.2001.tb04012.x","volume":"949","author":"R Day","year":"2001","unstructured":"Day R, National Surgical Adjuvant Breast and Bowel Projet P-1 study (NSABP-1). Quality of life and tamoxifen in a breast cancer prevention trial: a summary of findings from the NSABP P-1 study. National Surgical Adjuvant Breast and Bowel Project. Ann N Y Acad Sci. 2001;949:143\u201350. https:\/\/doi.org\/10.1111\/j.1749-6632.2001.tb04012.x.","journal-title":"Ann N Y Acad Sci"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01828-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:57:30Z","timestamp":1772621850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01828-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1828"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01828-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7522015\/v1","asserted-by":"object"}]},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no financial or non-financial competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}